Modified virus takes on Hard-to-Treat tumors in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called VG2062, which is a modified virus designed to attack cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose for f…
Phase: PHASE1 • Sponsor: Shanghai Virogin Biotech Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC